[en] INTRODUCTION: Demographic and clinical variables were examined in a post hoc analysis of the PROlonged Migraine Prevention with Topiramate (PROMPT) study to determine potential contribution to relapse. METHODS: After a six-month open-label (OL) topiramate phase, patients were randomised to continue topiramate or switch to placebo in a six-month double-blind (DB) phase. 'Relapse' was investigated in terms of change in monthly migraine days after randomisation compared with the month before randomisation, and was analysed during the first ('initial relapse') and last month ('sustained relapse') of the DB phase. More than 40 potential predicting factors were entered into analyses of variance and covariance. RESULTS: For initial relapse, variable-by-treatment interactions were significant for the Headache Impact Test (HIT-6) at DB baseline, and decline in acute medication intake or reporting of 'anxiety' in the OL phase. For sustained relapse, no statistically significant interactions were observed. CONCLUSION: Relapse after topiramate discontinuation in migraine prophylaxis appears to be unaffected by patient characteristics or baseline migraine frequency.
Disciplines :
Neurosciences & behavior Neurology
Author, co-author :
Schoenen, Jean ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Neuro-anatomie
Reuter, Uwe
Diener, Hans*-Christoph
Pfeil, Joop
Schwalen, Susanne
Schauble, Barbara
van Oene, Joop
Language :
English
Title :
Factors predicting the probability of relapse after discontinuation of migraine preventive treatment with topiramate.
Publication date :
2010
Journal title :
Cephalalgia
ISSN :
0333-1024
eISSN :
1468-2982
Publisher :
Blackwell Science, Osney Mead Oxford, United Kingdom
Dahlof C., Linde M. One-year prevalence of migraine in Sweden: a population-based study in adults. Cephalalgia 2001 ; 21: 664-671. (Pubitemid 32762789)
Lipton RB, Stewart WF, Diamond S., Diamond ML, Reed M. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache 2001 ; 41: 646-657. (Pubitemid 32777747)
Geraud G., Lanteri-Minet M., Lucas C., Valade D. French guidelines for the diagnosis and management of migraine in adults and children. Clin Ther 2004 ; 26: 1305-1318. (Pubitemid 39445352)
Evers S., Áfra J., Frese A., Goudsby PJ, Linde M., May A., et al. EFNS guideline on the drug treatment of migraine-report of an EFNS task force. Eur J Neurol 2006 ; 13: 560-572. (Pubitemid 43873628)
Steiner TJ, MacGregor EA, Davies PTG. Guidelines for all doctors in the diagnosis and management of migraine and tension-type headache. London: British Association for the Study of Headache, 2004.
Diener HC, Agosti R., Allais G., Bergmans P., Bussons G., Davies B., et al. Cessation versus continuation of 6-month migraine preventive therapy with topiramate (PROMPT): a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2007 ; 6: 1054-1062. (Pubitemid 350123606)
Rothrock JF, Parada VA, Drinkard R., Zweifler RM, Key KF Predictors of a negative response to topiramate therapy in patients with chronic migraine. Headache 2005 ; 45: 932-935. (Pubitemid 41045372)
Taylor AP, Adelman JU, Freeman MC Efficacy of duloxetine as a migraine preventive medication: possible predictors of response in a retrospective chart review. Headache 2007 ; 47: 1200-1203. (Pubitemid 47457773)